Subject: Real world evidence survey to assess the GERD patient management and usage of Sompraz-D in the treatment of GERD
Esomeprazole with domperidone is currently prescribed for the treatment of adult patients with gastroesophageal reflux disease (GERD), not responding to esomeprazole alone. Esomeprazole is the S-isomer of omeprazole and reduces gastric acid by specific inhibition of the H+/K+ ATPase in the gastric parietal cell. Domperidone belongs to dopamine Antagonist group. The gastroprokinetic properties of domperidone are related to its peripheral dopamine receptor blocking properties. Domperidone facilitates gastric emptying and decreases small bowel transit time by increasing esophageal and gastric peristalsis and by lowering esophageal sphincter pressure.
Although every new product is marketed only after regulatory approval, it is important to know how it performs in day-to-day practice of individual medical practitioners. For this purpose, we have planned to conduct a cross sectional study to assess the real-life performance of SOMPRAZ-D in GERD.
We invite you to participate in this cross-sectional study. All you need to do is to report on a standard form your experience with SOMPRAZ-D thus, this is not an experimental study.
If you agree to participate, you will need provide assessment response, on to the standard data collection form (which we call DCF). A monitor will assist you in verifying and collecting the DCF.
We trust you and we are partners in promoting safe and effective drug therapy. In that spirit we hope you will consent to participate in this study. If you do, please sign and return the enclosed reply along with your visiting card for accuracy of records.
|
}}){kind=logo}